Primary cutaneous aspergillosis in an immunocompetent patient: successful treatment with oral voriconazole.
We report a case of primary cutaneous aspergillosis in an immunocompetent child that responded rapidly to oral voriconazole therapy. Voriconazole may be considered as a treatment option for pediatric patients with primary cutaneous aspergillosis.
Craiglow
Brittany
B
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.
Hinds
Ginette
G
Antaya
Richard
R
Girardi
Michael
M
D000284:Administration, Oral; D000935:Antifungal Agents / Q000008:administration & dosage*; D001228:Aspergillosis / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D002921:Cicatrix / Q000473:pathology; D003881:Dermatomycoses / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007121:Immunocompetence; D007223:Infant; D008297:Male; D011743:Pyrimidines / Q000008:administration & dosage*; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole